Literature DB >> 32798319

Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma.

A Chirico1, M H Henderson Berg1, D Roberge2, K Pehr1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32798319     DOI: 10.1111/bjd.19490

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  1 in total

1.  Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab.

Authors:  Christian Menzer; Adriana Rendon; Jessica C Hassel
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.